# Kiniksa Pharmaceuticals International, plc (KNSA) · Edgar & Edgarette company card

> Kiniksa Pharmaceuticals International (KNSA) grew revenue 60.1% in FY2025 to $678 million, operating margin 11.4% against a -3.8% median for pharmaceutical preparations, equity 74.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1730430 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KNSA) · [JSON](https://www.pops4.com/boards/company/KNSA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $678M |
| Revenue growth, 1 year | 60.1% |
| Revenue growth per year | 104.8% |
| Operating margin | 11.4% (prior year -10.8%) |
| Net margin | 8.7% |
| Operating cash flow | $138M |
| Capital spending | $2M |
| Free cash flow | $136M |
| Cash | $166M |
| Long-term debt | — |
| Total assets | $764M |
| Total equity | $568M |
| Equity ÷ assets | 74.3% |
| Return on equity | 10.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.08 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -3.16 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $677.6M (FY2025). Experience: revenue up 60.1% on the year, up 104.8% a year over 4 years; operating margin 11.4%, up from -10.8%. Soundness: equity 74.3% of assets, return on equity 10.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $831.1M and $1.2B next year (method v4.1: its own 3-year record of growth weighed at 40% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $750.9M to $1.4B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 11.4% against a -3.8% median; growth 60.1% against 13.7%.

Range logged 2026-10-23, receipt d57d4fe4055fb39d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-22 ([filing](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000034/0001730430-26-000034-index.htm))

## Recent filings

- 10-Q · filed 2026-10-27 · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000110465926119186/0001104659-26-119186-index.htm)
- 8-K · filed 2026-10-27 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000037/0001730430-26-000037-index.htm)
- 8-K · filed 2026-10-22 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000034/0001730430-26-000034-index.htm)
- 10-Q · filed 2026-07-28 · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000110465926087545/0001104659-26-087545-index.htm)
- 8-K · filed 2026-07-28 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/0001730430-26-000031-index.htm)
- 8-K · filed 2026-05-29 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000029/0001730430-26-000029-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001730430.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1730430

## Cite

POPS4, Edgar & Edgarette: Kiniksa Pharmaceuticals International, plc (KNSA) company card, from the company's own SEC filings, accessed 2026-11-02, https://www.pops4.com/boards/company/KNSA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.